Abeona Therapeutics (ABEO) Price & Analysis

Compare

1,409 Followers

ABEO Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.93 - $7.32

Previous CloseN/A

Volume71.38K

Average Volume (3M)923.20K

Market Cap

$330.98M

Enterprise Value$176.43M

Total Cash (Recent Filing)$84.16M

Total Debt (Recent Filing)$23.98M

Price to Earnings (P/E)―

Beta0.97

Next Earnings

Aug 18, 2025

EPS Estimate

-0.39

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.24

Shares Outstanding51,156,734

10 Day Avg. Volume579,101

30 Day Avg. Volume923,203

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.53

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-176.43

Enterprise Value/Ebitda-4.78

Forecast

1Y Price Target

$21.63

Price Target Upside234.31% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Commercial LaunchThe U.S. launch of ZEVASKYN is under way, with expectations for steady uptake and activation of additional treatment centers.

Financial StabilityAbeona announced the sale of its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $155M, providing sufficient cash for more than two years of operating expenses.

Regulatory ProgressThe FDA approved the Biologics License Application for Abeona's lead candidate, prademagene zamikeracel, signaling confidence in its treatment potential.

Bears Say

Market RisksRisks include slower than projected uptake for pz-cel in the United States upon market introduction and setbacks with earlier-stage pipeline programs.

Pricing ConcernsZEVASKYN's list price is significantly higher than initially forecasted, suggesting a strong revenue potential for Abeona.

Abeona Therapeutics News

Abeona Therapeutics announces employee inducement grants

Abeona Therapeutics (ABEO) granted equity awards to new non-executive employees who joined the Company. The equity awards were...

7d ago

ABEO

AscellaHealth highlights value of HUB partnership with Abeona Therapeutics

AscellaHealth highlights the value of its HUB partnership with Abeona Therapeutics (ABEO) in the pre-and-post launch commercialization of...

10d ago

ABEO

Abeona announces ZEVASKYN available at new Qualified Treatment Center

Abeona Therapeutics (ABEO) announced activation of the newest Qualified Treatment Center for FDA-approved ZEVASKYN gene-modified cellular sheets. This...

24d ago

ABEO

Abeona Therapeutics Amends Loan Agreement with Avenue

An update from Abeona Therapeutics ( ($ABEO) ) is now available. On July 18, 2025, Abeona Therapeutics Inc....

21d ago

ABEO

Abeona Therapeutics’ Gene Therapy Trial for MPS IIIA: A Promising Update

Abeona Therapeutics Inc (($ABEO)) announced an update on their ongoing clinical study. Abeona Therapeutics Inc, in collaboration with...

22d ago

ABEO

Positive Outlook for Abeona Therapeutics Amid FDA Challenges and Promising ZEVASKYN Launch

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Abeona Therapeutics today and set a price target...

25d ago

ABEO

Fair Isaac, Aeva, Abeona, Cipher, Verisign: Insider Sales Unveiled!

Insiders have been trading these 5 stocks: (($FICO)), (($AEVA)), (($ABEO)), (($CIFR)) and (($VRSN)). Here is a breakdown of...

27d ago

ABEO

AEVA

Abeona Therapeutics Sells Priority Review Voucher for $155M

Abeona Therapeutics ( ($ABEO) ) just unveiled an announcement. On June 27, 2025, Abeona Therapeutics completed the sale...

1M ago

ABEO

Abeona Therapeutics closes sale of Rare Pediatric Disease PRV for $155M

Abeona Therapeutics (ABEO) announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher, PRV,...

1M ago

ABEO

Abeona Therapeutics announces option exercise by Beacon Therapeutics

Abeona Therapeutics (ABEO) announced that Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, has exercised...

1M ago

ABEO

Abeona Therapeutics announces employee inducement grants

Abeona has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved...

1M ago

ABEO

Abeona Therapeutics added to membership of Russell 2000, Russell 3000

Abeona Therapeutics (ABEO) announced that it was added as a member of the U.S. small-cap Russell 2000 Index...

1M ago

ABEO

Abeona Therapeutics Advances DEB Treatment with Phase 3b Study

Abeona Therapeutics Inc (($ABEO)) announced an update on their ongoing clinical study. Abeona Therapeutics Inc is conducting a...

1M ago

ABEO

Abeona Therapeutics announces publication in The Lancet of Phase 3 VITAL study

Abeona Therapeutics (ABEO) announced that The Lancet has published results from the pivotal Phase 3 VIITAL study evaluating...

2M ago

ABEO

ABEO FAQ

What was Abeona Therapeutics Inc’s price range in the past 12 months?

Abeona Therapeutics Inc lowest stock price was $3.93 and its highest was $7.32 in the past 12 months.

What is Abeona Therapeutics Inc’s market cap?

Abeona Therapeutics Inc’s market cap is $330.98M.

When is Abeona Therapeutics Inc’s upcoming earnings report date?

Abeona Therapeutics Inc’s upcoming earnings report date is Aug 18, 2025 which is in 10 days.

How were Abeona Therapeutics Inc’s earnings last quarter?

Abeona Therapeutics Inc released its earnings results on May 15, 2025. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.358 by $0.118.

Is Abeona Therapeutics Inc overvalued?

According to Wall Street analysts Abeona Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Abeona Therapeutics Inc pay dividends?

Abeona Therapeutics Inc does not currently pay dividends.

What is Abeona Therapeutics Inc’s EPS estimate?

Abeona Therapeutics Inc’s EPS estimate is -0.39.

How many shares outstanding does Abeona Therapeutics Inc have?

Abeona Therapeutics Inc has 51,156,734 shares outstanding.

What happened to Abeona Therapeutics Inc’s price movement after its last earnings report?

Abeona Therapeutics Inc reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.358. Following the earnings report the stock price went up 7.421%.

Which hedge fund is a major shareholder of Abeona Therapeutics Inc?

Currently, no hedge funds are holding shares in ABEO

Abeona Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-271.78%

Trailing 12-Months

Asset Growth

32.79%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Abeona Therapeutics Inc

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.

Abeona Therapeutics (ABEO) Earnings & Revenues

Historic Earnings Reports

ABEO Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted the successful FDA approval and positive market reception of ZEVASKYN, as well as strategic financial moves to ensure the company's stability. However, delays in patient treatment and increased operating expenses were noted as challenges.View all ABEO earnings summaries

ABEO Stock 12 Month Forecast

Average Price Target

$21.63

▲(234.31% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","28":"$28","9.25":"$9.25","15.5":"$15.5","21.75":"$21.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":27.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$27.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.63,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$19.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,9.25,15.5,21.75,28],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.57,7.256923076923077,8.943846153846154,10.630769230769232,12.317692307692308,14.004615384615384,15.691538461538462,17.37846153846154,19.065384615384616,20.752307692307692,22.439230769230768,24.126153846153848,25.813076923076924,{"y":27.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.57,6.805384615384615,8.04076923076923,9.276153846153846,10.51153846153846,11.746923076923077,12.982307692307693,14.217692307692307,15.453076923076923,16.68846153846154,17.923846153846153,19.159230769230767,20.394615384615385,{"y":21.63,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.57,6.603076923076923,7.636153846153846,8.669230769230769,9.702307692307691,10.735384615384614,11.768461538461539,12.801538461538462,13.834615384615384,14.867692307692307,15.90076923076923,16.933846153846154,17.966923076923077,{"y":19,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.38,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.2,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.81,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.46,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.25,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.34,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.57,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.54,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.24,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.45,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.87,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.28,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.57,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >